All posts by: Michael Zand

About Michael Zand

Potential CRISPR setback jolts investors, but researchers say there’s no need to panic – Genetic Literacy Project

Continue reading

2018-01-11 NEWS

Genetic Literacy Project

Potential CRISPR setback jolts investors, but researchers say there’s no need to panic
Genetic Literacy Project
On [January 8], the world of science awoke to news that suddenly cast uncomfortable doubt on many of the past five years’ major breakthroughs: A new paper had identified a possible barrier to using the revolutionary gene-editing tool CRISPR-Cas9 in

and more »

Continue reading

2018-01-11 NEWS

Science Daily

‘Decorated’ stem cells could offer targeted heart repair
Science Daily
“Platelets can home in on an injury site and stay there, and even in some cases recruit a body’s own naturally occurring stem cells to the site, but they are a double-edged sword,” says Cheng, associate professor of veterinary medicine and associate

and more »

Continue reading

2018-01-11 NEWS

Removing the Immunotherapy Blindfold
UConn Today
“While immunotherapy holds incredible promise, it’s currently like going into battle with high tech weapons wearing a blindfold,” explains Qendro. “In patients who respond well, the outcomes are really significant, but without the personalized

Continue reading

2018-01-11 NEWS

Xconomy

Notes From the JPM ’18 Vortex: Gene Therapy’s Reckoning and Lonely Cabs
Xconomy
The annual J.P. Morgan Healthcare conference in San Francisco winds down today, meaning the remaining stragglers are either presenting to half-empty rooms or headed back to colder climes. Compared to a 2017 full of scientific milestones—FDA approvals